SUPPLY of LUTATHERA� (lutetium Lu 177 dotatate) and PLUVICTO� (lutetium Lu 177 vipivotide tetraxetan)
12481254 · DEPT OF DEFENSE
A federal solicitation, performed in Bethesda, MD. AwardCast estimates what this specific solicitation will close for, before you bid.
What's being bought
Clinical Utility: It is used for targeted radioligand therapy for specific types of prostate cancer within the Nuclear Medicine Division of the Department of Radiology at WRNMMC. Novartis Pharmaceuticals Corporation is the sole source for Pluvicto. Therefore, the recommended course of action is to a
Comparable recent awards
| Winner | Award value | Offers | Date |
|---|---|---|---|
| Detail available to signed-in users. | |||
Questions
What is solicitation 12481254?
SUPPLY of LUTATHERA� (lutetium Lu 177 dotatate) and PLUVICTO� (lutetium Lu 177 vipivotide tetraxetan), issued by DEPT OF DEFENSE, performed in Bethesda, MD.
Explore the market
Forecast Report — what a specific solicitation will close for: the predicted price range, the competition to expect, and comparable awards already closed. Before you price your bid.
Every forecast is scored against the real award once it becomes public. See the track record.
Closed awards from public federal data, not the forecast. One email, no account.
Or get the forecast for this solicitation — $49, one report.